|
|
Post by dreamboatcruise on May 27, 2017 22:00:59 GMT -5
A lot of the problem is simply getting people to take their diabetes seriously. Type 2 diabetes has little visible penalty for non-compliance until things start to go badly wrong and that can take a decade or so. You are getting people to change their lifestyle and that is always hard. You are exactly correct. However its more than just the T2s. Its also the medications they are given and who is giving them these pills? Once CGMs become standard for T2s there is no place to hide the numbers. The T2s will now know what is going on and the doctors can no longer hide behind the pills. T2s need to address their mealtime sugar spikes which in many cases can go 200+. Metformin nor baslin insulin nor lifestyle changes can address these spikes. The only thing which can is mealtime insulin. While low carb diets can help, afrezza pretty much obsoletes the need for things like the Bernstein diet. With afrezza they are better to have a well balanced lower fat diet. Exercise is great but again that is not going to address the 200+ mealtime spike. Only afrezza can provide the needed first phase insulin release to shut off the liver's glucose production which T2s lose and only insulin can lower high BG. As Dr. Bruce Bode said a few weeks back all T2s should be on afrezza within a year of two of diagnosis but I would say sooner. Metformin is a HUGE part of the problem in that it masks the problem by slowly bringing down the BG by reducing glucose production by the liver. This leaves the PWD in the 140+ range for extended periods as they incur micro-vascular damage and 70+% are not even meeting the 7 A1C. Its not only crazy but down right dangerous in the long term for the PWD. In short metformin maybe the worst thing a PWD can be given because it masks the problem, high mealtime sugar. In the end this just makes a big mess and if the PWD lives long enough they end up on insulin anyway. How many diabetics are dying from heart attacks? Who knows as its not currently tracked. Then again if you follow Dr Bodes advice afrezza obsoletes all current T2 medications and pretty much all use of basal insulin for T2s as they will never need it. This is about a $20B disruption to the current market so I would say Big Pharma will do all it can so that the T2s never ever see their numbers. While what Dexcom is doing will help, hopefully Tim Cook and Apple have other ideas so everyone sees their numbers and there is no longer a place to hide. Hopefully Dexcom comes with an army including Tim Cook, MNKD, Onduo and others to the ADA conference for the discussion on "Should T2s be given CGMs". The last thing the status quo wants is for T2s to know their numbers so unless they do we already know the answer, NO. What a mess it would make. Well, there are two issues with CGMs for T2. One is insurance coverage, but the other is most T2 would likely strongly resist having one until quite long into progression... IMO, based on T2s I've known but also what others have said here. The ones that aren't doing what they should do, are very unlikely to want to have an invasive device attached to them... doesn't fit with pretending the problem doesn't exist. Possibly a non-invasive solution could change that, if one comes anytime soon. |
|
|
|
Post by kc on May 27, 2017 22:28:56 GMT -5
Just think if instead of VDEX MannKind made a deal with Walgreens healthcare clinic's or CVS Minute Clinics and targeted both T1D and TD2 patients Tied into the One Drop Technology. Think about how many opportunities the company would have to sell the product. While VDEX has not been the success any of us said hope for perhaps MannKind should try to do a test market with either Walgreens or CVS.
|
|
|
|
Post by dreamboatcruise on May 28, 2017 2:16:03 GMT -5
Just think if instead of VDEX MannKind made a deal with Walgreens healthcare clinic's or CVS Minute Clinics and targeted both T1D and TD2 patients Tied into the One Drop Technology. Think about how many opportunities the company would have to sell the product. While VDEX has not been the success any of us said hope for perhaps MannKind should try to do a test market with either Walgreens or CVS. Drug manufacturers are not allowed to "make deals" with doctors to prescribe their medications... at least not if the doctors accept any kind of government funded health payments (Medicare, Medicaid, etc.), which I'm sure all of those clinics do. VDEX did not have any connection financially with MNKD... there was no deal, it was simply founded by people that believed in Afrezza, and very well might have had an investment in MNKD, but that apparently isn't against the rules despite seemingly causing the same sort of financial conflict of interest. |
|
|
|
Post by sayhey24 on May 28, 2017 4:39:54 GMT -5
You are exactly correct. However its more than just the T2s. Its also the medications they are given and who is giving them these pills? Once CGMs become standard for T2s there is no place to hide the numbers. The T2s will now know what is going on and the doctors can no longer hide behind the pills. T2s need to address their mealtime sugar spikes which in many cases can go 200+. Metformin nor baslin insulin nor lifestyle changes can address these spikes. The only thing which can is mealtime insulin. While low carb diets can help, afrezza pretty much obsoletes the need for things like the Bernstein diet. With afrezza they are better to have a well balanced lower fat diet. Exercise is great but again that is not going to address the 200+ mealtime spike. Only afrezza can provide the needed first phase insulin release to shut off the liver's glucose production which T2s lose and only insulin can lower high BG. As Dr. Bruce Bode said a few weeks back all T2s should be on afrezza within a year of two of diagnosis but I would say sooner. Metformin is a HUGE part of the problem in that it masks the problem by slowly bringing down the BG by reducing glucose production by the liver. This leaves the PWD in the 140+ range for extended periods as they incur micro-vascular damage and 70+% are not even meeting the 7 A1C. Its not only crazy but down right dangerous in the long term for the PWD. In short metformin maybe the worst thing a PWD can be given because it masks the problem, high mealtime sugar. In the end this just makes a big mess and if the PWD lives long enough they end up on insulin anyway. How many diabetics are dying from heart attacks? Who knows as its not currently tracked. Then again if you follow Dr Bodes advice afrezza obsoletes all current T2 medications and pretty much all use of basal insulin for T2s as they will never need it. This is about a $20B disruption to the current market so I would say Big Pharma will do all it can so that the T2s never ever see their numbers. While what Dexcom is doing will help, hopefully Tim Cook and Apple have other ideas so everyone sees their numbers and there is no longer a place to hide. Hopefully Dexcom comes with an army including Tim Cook, MNKD, Onduo and others to the ADA conference for the discussion on "Should T2s be given CGMs". The last thing the status quo wants is for T2s to know their numbers so unless they do we already know the answer, NO. What a mess it would make. Well, there are two issues with CGMs for T2. One is insurance coverage, but the other is most T2 would likely strongly resist having one until quite long into progression... IMO, based on T2s I've known but also what others have said here. The ones that aren't doing what they should do, are very unlikely to want to have an invasive device attached to them... doesn't fit with pretending the problem doesn't exist. Possibly a non-invasive solution could change that, if one comes anytime soon. From personal experience I found the Libre much better than pricking my finger 10x per day which will be required for initial titration. After about a month most T2s will pretty much know their numbers and know their routine. I gave my reader to a friend. The big thing is seeing the trends during the day before and after different foods and also at night. I would be shocked if a newly diagnosed T2 would not be willing to use the Libre or Verily's M&M CGM. At the same time the Libre runs about $70 for a 14 day sensor and another $100 for the reader. The sensors are pretty much covered by insurance and I saw someone maybe Vdex had a loaner program for Dexcom. I would think a similar loaner on the Libre reader would make a lot of sense. 15 minutes is good enough to see the trends and I would think a meter reading prior to taking a second hit of afrezza would be prudent. I think Tim Cook may have other plans and have all IWatch users CGM enabled. My understanding is they currently have a fairly large test group walking around the Bay area trying out the new band. When that happens and PWDs start seeing their numbers current T2 treatments will go the way of the landline. Who is not going to opt for a free IWatch if their insurance covers it? Then again if the bands do not need to be replaced every week or two current CGM makers may never crack into the T2 market. The thing which drives me crazy are statements like "until quite long into progression". We have 40+ years of studies all saying early insulin intervention in most cases will stop the progression. We had Al Mann saying the same thing with their T2 testing with afrezza. With CGMs and afrezza in most cases this progression can be stopped. How about we stop the progression and add 10+ years to these peoples lives? |
|
|
|
Post by golfeveryday on May 28, 2017 9:19:44 GMT -5
Well, there are two issues with CGMs for T2. One is insurance coverage, but the other is most T2 would likely strongly resist having one until quite long into progression... IMO, based on T2s I've known but also what others have said here. The ones that aren't doing what they should do, are very unlikely to want to have an invasive device attached to them... doesn't fit with pretending the problem doesn't exist. Possibly a non-invasive solution could change that, if one comes anytime soon. From personal experience I found the Libre much better than pricking my finger 10x per day which will be required for initial titration. After about a month most T2s will pretty much know their numbers and know their routine. I gave my reader to a friend. The big thing is seeing the trends during the day before and after different foods and also at night. I would be shocked if a newly diagnosed T2 would not be willing to use the Libre or Verily's M&M CGM. At the same time the Libre runs about $70 for a 14 day sensor and another $100 for the reader. The sensors are pretty much covered by insurance and I saw someone maybe Vdex had a loaner program for Dexcom. I would think a similar loaner on the Libre reader would make a lot of sense. 15 minutes is good enough to see the trends and I would think a meter reading prior to taking a second hit of afrezza would be prudent. I think Tim Cook may have other plans and have all IWatch users CGM enabled. My understanding is they currently have a fairly large test group walking around the Bay area trying out the new band. When that happens and PWDs start seeing their numbers current T2 treatments will go the way of the landline. Who is not going to opt for a free IWatch if their insurance covers it? Then again if the bands do not need to be replaced every week or two current CGM makers may never crack into the T2 market. The thing which drives me crazy are statements like "until quite long into progression". We have 40+ years of studies all saying early insulin intervention in most cases will stop the progression. We had Al Mann saying the same thing with their T2 testing with afrezza. With CGMs and afrezza in most cases this progression can be stopped. How about we stop the progression and add 10+ years to these peoples lives? Well said. Agree with you. 15 years ago, Prandin was well before its time for T2. Lilly and GSK were good at convincing docs insulin resistance was the main cause of high blood sugar in T2. CGM will eventually pull the curtain on how bad T2 Diabetes treatments are currently. It is amazing to me the medical community would allow current treatment recommendations to be allowed. Put a bandaid on it until it doesn't work, then put a bigger bandaid on it, followed by a bigger bandaid. Finally stitch the wound after it is completely infected and gnarly. Basically same as diet exercise, one pill, two pills, basal insulin, then finally mealtime insulin. All the while microvascular and eventually macrovascular issues are slowly killing people. Joke. |
|
|
|
Post by themarlin on May 28, 2017 9:30:44 GMT -5
You are exactly correct. However its more than just the T2s. Its also the medications they are given and who is giving them these pills? Once CGMs become standard for T2s there is no place to hide the numbers. The T2s will now know what is going on and the doctors can no longer hide behind the pills. T2s need to address their mealtime sugar spikes which in many cases can go 200+. Metformin nor baslin insulin nor lifestyle changes can address these spikes. The only thing which can is mealtime insulin. While low carb diets can help, afrezza pretty much obsoletes the need for things like the Bernstein diet. With afrezza they are better to have a well balanced lower fat diet. Exercise is great but again that is not going to address the 200+ mealtime spike. Only afrezza can provide the needed first phase insulin release to shut off the liver's glucose production which T2s lose and only insulin can lower high BG. As Dr. Bruce Bode said a few weeks back all T2s should be on afrezza within a year of two of diagnosis but I would say sooner. Metformin is a HUGE part of the problem in that it masks the problem by slowly bringing down the BG by reducing glucose production by the liver. This leaves the PWD in the 140+ range for extended periods as they incur micro-vascular damage and 70+% are not even meeting the 7 A1C. Its not only crazy but down right dangerous in the long term for the PWD. In short metformin maybe the worst thing a PWD can be given because it masks the problem, high mealtime sugar. In the end this just makes a big mess and if the PWD lives long enough they end up on insulin anyway. How many diabetics are dying from heart attacks? Who knows as its not currently tracked. Then again if you follow Dr Bodes advice afrezza obsoletes all current T2 medications and pretty much all use of basal insulin for T2s as they will never need it. This is about a $20B disruption to the current market so I would say Big Pharma will do all it can so that the T2s never ever see their numbers. While what Dexcom is doing will help, hopefully Tim Cook and Apple have other ideas so everyone sees their numbers and there is no longer a place to hide. Hopefully Dexcom comes with an army including Tim Cook, MNKD, Onduo and others to the ADA conference for the discussion on "Should T2s be given CGMs". The last thing the status quo wants is for T2s to know their numbers so unless they do we already know the answer, NO. What a mess it would make. Well, there are two issues with CGMs for T2. One is insurance coverage, but the other is most T2 would likely strongly resist having one until quite long into progression... IMO, based on T2s I've known but also what others have said here. The ones that aren't doing what they should do, are very unlikely to want to have an invasive device attached to them... doesn't fit with pretending the problem doesn't exist. Possibly a non-invasive solution could change that, if one comes anytime soon. The US is a large market but there are many others. Big pharma is there too but insurance and governments might be smaller and more nimble and welcome and support 'new' technology (CGM's/Afrezza) more openly and quickly. |
|
|
|
Post by kc on May 28, 2017 9:32:36 GMT -5
Just think if instead of VDEX MannKind made a deal with Walgreens healthcare clinic's or CVS Minute Clinics and targeted both T1D and TD2 patients Tied into the One Drop Technology. Think about how many opportunities the company would have to sell the product. While VDEX has not been the success any of us said hope for perhaps MannKind should try to do a test market with either Walgreens or CVS. Drug manufacturers are not allowed to "make deals" with doctors to prescribe their medications... at least not if the doctors accept any kind of government funded health payments (Medicare, Medicaid, etc.), which I'm sure all of those clinics do. VDEX did not have any connection financially with MNKD... there was no deal, it was simply founded by people that believed in Afrezza, and very well might have had an investment in MNKD, but that apparently isn't against the rules despite seemingly causing the same sort of financial conflict of interest. My words dictated didn't come across correctly. I know that MannKind did not make a deal with VDEX. It would also be up to the managers of a Minute clinic or Walgreens Healthclinic to set up their own diabetes clinic. But it does seem like it would be a winner. |
|
|
|
Post by agedhippie on May 28, 2017 9:43:36 GMT -5
Drug manufacturers are not allowed to "make deals" with doctors to prescribe their medications... at least not if the doctors accept any kind of government funded health payments (Medicare, Medicaid, etc.), which I'm sure all of those clinics do. VDEX did not have any connection financially with MNKD... there was no deal, it was simply founded by people that believed in Afrezza, and very well might have had an investment in MNKD, but that apparently isn't against the rules despite seemingly causing the same sort of financial conflict of interest. My words dictated didn't come across correctly. I know that MannKind did not make a deal with VDEX. It would also be up to the managers of a Minute clinic or Walgreens Healthclinic to set up their own diabetes clinic. But it does seem like it would be a winner. So the manager would leave CVS/Walgreens and set up their own business? |
|
|
|
Post by dreamboatcruise on May 28, 2017 11:24:50 GMT -5
Well, there are two issues with CGMs for T2. One is insurance coverage, but the other is most T2 would likely strongly resist having one until quite long into progression... IMO, based on T2s I've known but also what others have said here. The ones that aren't doing what they should do, are very unlikely to want to have an invasive device attached to them... doesn't fit with pretending the problem doesn't exist. Possibly a non-invasive solution could change that, if one comes anytime soon. From personal experience I found the Libre much better than pricking my finger 10x per day which will be required for initial titration. After about a month most T2s will pretty much know their numbers and know their routine. I gave my reader to a friend. The big thing is seeing the trends during the day before and after different foods and also at night. I would be shocked if a newly diagnosed T2 would not be willing to use the Libre or Verily's M&M CGM. At the same time the Libre runs about $70 for a 14 day sensor and another $100 for the reader. The sensors are pretty much covered by insurance and I saw someone maybe Vdex had a loaner program for Dexcom. I would think a similar loaner on the Libre reader would make a lot of sense. 15 minutes is good enough to see the trends and I would think a meter reading prior to taking a second hit of afrezza would be prudent. I think Tim Cook may have other plans and have all IWatch users CGM enabled. My understanding is they currently have a fairly large test group walking around the Bay area trying out the new band. When that happens and PWDs start seeing their numbers current T2 treatments will go the way of the landline. Who is not going to opt for a free IWatch if their insurance covers it? Then again if the bands do not need to be replaced every week or two current CGM makers may never crack into the T2 market. The thing which drives me crazy are statements like "until quite long into progression". We have 40+ years of studies all saying early insulin intervention in most cases will stop the progression. We had Al Mann saying the same thing with their T2 testing with afrezza. With CGMs and afrezza in most cases this progression can be stopped. How about we stop the progression and add 10+ years to these peoples lives? Based on one article about the Apple Watch CGM effort it appears that Apple is taking the approach of not officially targeting it for use by patients with diabetes... it is officially meant for use by the general population. Supposedly to get around need for FDA approval. That is double edge sword, however. Obviously big benefit in time to market, but insurance isn't going to pay for a device that isn't FDA approved. I would assume many PWD might choose to buy one anyway, especially if they already use an iPhone... if I had diabetes I'd likely want a non-invasive CGM even if not as accurate as finger stick... though unlikely to switch to Apple from Android just to get CGM with Apple Watch. I would be very resistant to using an invasive CGM, myself. |
|
|
|
Post by sayhey24 on May 29, 2017 3:07:05 GMT -5
From personal experience I found the Libre much better than pricking my finger 10x per day which will be required for initial titration. After about a month most T2s will pretty much know their numbers and know their routine. I gave my reader to a friend. The big thing is seeing the trends during the day before and after different foods and also at night. I would be shocked if a newly diagnosed T2 would not be willing to use the Libre or Verily's M&M CGM. At the same time the Libre runs about $70 for a 14 day sensor and another $100 for the reader. The sensors are pretty much covered by insurance and I saw someone maybe Vdex had a loaner program for Dexcom. I would think a similar loaner on the Libre reader would make a lot of sense. 15 minutes is good enough to see the trends and I would think a meter reading prior to taking a second hit of afrezza would be prudent. I think Tim Cook may have other plans and have all IWatch users CGM enabled. My understanding is they currently have a fairly large test group walking around the Bay area trying out the new band. When that happens and PWDs start seeing their numbers current T2 treatments will go the way of the landline. Who is not going to opt for a free IWatch if their insurance covers it? Then again if the bands do not need to be replaced every week or two current CGM makers may never crack into the T2 market. The thing which drives me crazy are statements like "until quite long into progression". We have 40+ years of studies all saying early insulin intervention in most cases will stop the progression. We had Al Mann saying the same thing with their T2 testing with afrezza. With CGMs and afrezza in most cases this progression can be stopped. How about we stop the progression and add 10+ years to these peoples lives? Based on one article about the Apple Watch CGM effort it appears that Apple is taking the approach of not officially targeting it for use by patients with diabetes... it is officially meant for use by the general population. Supposedly to get around need for FDA approval. That is double edge sword, however. Obviously big benefit in time to market, but insurance isn't going to pay for a device that isn't FDA approved. I would assume many PWD might choose to buy one anyway, especially if they already use an iPhone... if I had diabetes I'd likely want a non-invasive CGM even if not as accurate as finger stick... though unlikely to switch to Apple from Android just to get CGM with Apple Watch. I would be very resistant to using an invasive CGM, myself. If you had diabetes would you rather poke yourself too many times a day our take the Libre and attach it for a few weeks with no pokes let alone Verily's which is the size of an M&M? For me it was a no-brainer to go on ebay and get the Libre reader and sensors. I hate poking my finger even though too many people say it doesn't hurt, I guess it depends on your fingers. With me sometimes it does and sometimes not but more times it does. If you are really going to properly titrate afrezza and if you are really trying to get near non-diabetic numbers you will take a minimum of 10 readings and then log your food plus any additionally doses needed for a few weeks until you see the patterns. But even with the pokes you won't see the 24x7 patterns you get with the Libre or other CGMs. Is Cook's non-invasive CGM be good enough to dose? Probably not but it will pull the curtain back for the first time and give the general public a look at their BG levels. It will also start the conversation. Currently most T2s have no idea what their post meal BGs are let alone their pre-meal numbers. They are currently told to test in the morning like they are all T1s on basal. How many people are walking around and have no idea they are diabetic. I bet a ton. I am not sure who is going to pay for Cook's watch. I am surprised at how many people seem to be wearing them now after taking a while to catch on. Right now insurance pays for the test strips and what do some do, they turn around and sell the box for $10. I think the big challenge will be educating the general public on what T2 treatment should be which is treating their meal time spikes. With Cook's help and hopefully others like Verily the general public should be able to see these spikes for the first time. Changing how PCPs treat T2s is going to be a huge change and its not going to be easy but once the PWDs understand that the pills are making things worse and when they demand change things will happen fast. The better CGMs will be there soon and afrezza already is. Stefan Schwarz learned quickly changing PCP T2 treatment was going to be hard, pulled back and started a new company to address the problem. Will Onduo be a success? Lets hope. IMO, its going to take big advertising, some paid but more earned on things like the talk shows and news shows like 60 minutes. Brandicourt once said afrezza would start catching on in 2020. Maybe he and Schwarz really understand the challenge and what it will take. |
|
|
|
Post by swanybuaya on Jun 2, 2017 17:40:42 GMT -5
Did anyone go to VDEX's grand opening event June 1st in Canoga Park?
|
|
bac
Lab Rat
Posts: 37
|
Post by bac on Jun 2, 2017 19:31:41 GMT -5
Called Thursday and briefly talked to Steve, in management at VDEX. Steve said the office was closed that day and there was no grand reopening. He asked me to stop in next Friday, one week from today.
|
|
|
|
Post by sla55 on Jun 10, 2017 6:48:27 GMT -5
On VDEX Diabetes Facebook page:
Vdex Diabetes
8 hrs ·
Understanding HbA1c
“Hemoglobin A1c,” “HbA1c,” or just “A1c” for short, is a measure of a persons’ average blood sugar levels. It is determined through a simple test that can be performed in a doctor’s office or a lab. Since blood sugar levels are an important factor of overall health, everyone should know their HbA1c number, whether diabetic, prediabetic, or nondiabetic.
Normal HbA1c levels are from about 4.5 – 5.7. Prediabetic levels are 5.8 – 6.4, and the diagnosis of diabetes is 6.5 and above. Since HbA1c is an average, it carries with it the deficiency of all averages. Mark Twain said it best, “A man with one foot in a bucket of ice water and the other foot in a bucket of scalding water is, on average, comfortable.” That quote really captures one of the problems of A1c. A person with diabetes who has a reasonable A1c might only have that because the high blood sugar levels are counterbalanced by dangerously low levels.
With blood sugar, very high levels or very low levels are damaging to the body. High levels maintained over long periods of time literally degrade tissue and can lead to complications like heart attack, stroke, kidney failure, blindness, erectile dysfunction, and the list goes on. By contrast, very low levels for even fairly short periods like an hour or so can lead to disorientation, brain damage, coma and even death.
In the healthy person, the body’s natural mechanisms operate to keep blood sugar levels very stable. As HbA1c levels rise, it’s an indication that blood sugar levels are becoming unstable. HbA1c can be thought of as the canary in the coal mine.
|
|
|
|
Post by peppy on Jun 10, 2017 7:39:16 GMT -5
From personal experience I found the Libre much better than pricking my finger 10x per day which will be required for initial titration. After about a month most T2s will pretty much know their numbers and know their routine. I gave my reader to a friend. The big thing is seeing the trends during the day before and after different foods and also at night. I would be shocked if a newly diagnosed T2 would not be willing to use the Libre or Verily's M&M CGM. At the same time the Libre runs about $70 for a 14 day sensor and another $100 for the reader. The sensors are pretty much covered by insurance and I saw someone maybe Vdex had a loaner program for Dexcom. I would think a similar loaner on the Libre reader would make a lot of sense. 15 minutes is good enough to see the trends and I would think a meter reading prior to taking a second hit of afrezza would be prudent. I think Tim Cook may have other plans and have all IWatch users CGM enabled. My understanding is they currently have a fairly large test group walking around the Bay area trying out the new band. When that happens and PWDs start seeing their numbers current T2 treatments will go the way of the landline. Who is not going to opt for a free IWatch if their insurance covers it? Then again if the bands do not need to be replaced every week or two current CGM makers may never crack into the T2 market. The thing which drives me crazy are statements like "until quite long into progression". We have 40+ years of studies all saying early insulin intervention in most cases will stop the progression. We had Al Mann saying the same thing with their T2 testing with afrezza. With CGMs and afrezza in most cases this progression can be stopped. How about we stop the progression and add 10+ years to these peoples lives? Based on one article about the Apple Watch CGM effort it appears that Apple is taking the approach of not officially targeting it for use by patients with diabetes... it is officially meant for use by the general population. Supposedly to get around need for FDA approval. That is double edge sword, however. Obviously big benefit in time to market, but insurance isn't going to pay for a device that isn't FDA approved. I would assume many PWD might choose to buy one anyway, especially if they already use an iPhone... if I had diabetes I'd likely want a non-invasive CGM even if not as accurate as finger stick... though unlikely to switch to Apple from Android just to get CGM with Apple Watch. I would be very resistant to using an invasive CGM, myself. quote: Apple is taking the approach of not officially targeting it for use by patients with diabetes... it is officially meant for use by the general population. Supposedly to get around need for FDA approval. reply: brilliant. We know how many people own iphones. people with iphones will enjoy the application. I will buy a new iphone just for the application. it really is fun to see what blood, Interstitial glucose does with food and exercise.
|
|
|
|
Post by sayhey24 on Jun 10, 2017 7:54:52 GMT -5
When I explain the value of the A1c measurement to people I equate it to a car's "average miles per gallon". A1c is really not much use when on a day to day, hour to hour basis a PWD needs to know what their current sugar level is. What they need is a speedometer which we now have with continuous glucose monitors.
Now an A1c of 5.7 is about an average BG level of 111. The question which needs to be asked is what is the PWD's BG 1hour and 2 hours after eating and eating what as only carbs will raise sugar levels. Most T2s currently being treated with metformin are seeing post meal spikes over 200+. They then spend hours over 140 which is considered the magic number for microvasclular damage. Metformin does nothing to address root cause - not enough insulin at meal time. The SGLT2 and other non-insulin treatments just create a bigger mess.
The real question is does the medical community want to address the root cause of T2 diabetes which is the pancreas not producing enough insulin at meal time or not? I am not so sure. Maybe if they understood diabetes better and the current medications better some would. There is only one way to address meal time sugar spikes and that is mealtime insulin. CGMs make things so easy and the introduction of the Abbott Libre which Mike C said should be available in the U.S. soon make CGMs almost affordable for everyone.
I suspect many doctors want to continue to treat T2 diabetes as a black art and keep the PWDs in the dark. There is an ADA session Sunday at 2pm as to whether T2's should be using CGMs. Thats almost like asking should cars have speedometers.
I am hoping Dachis is showing at ADA with the Libre interfacing with an android and then sending that data to his monitoring system. The NFC andriod app is already available from Abbott. I also see David Cheng is back at ADA with Glutalor which is the San Meditec CGM from China. This is a CGM which could be brought to markets for pennies on the dollar compared to the Dexcom and its #1 in China.
|
|
